Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics
Alternative Names: 18F-Ge-148; 18F fluciclovine; [18F]-FACBC; Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-fluorine-18-fluorocyclobutane-1-carboxylic acid; Anti-18-F-FACBC; Anti-18F-FABC; Anti-3-18F-FACBC; Anti-F-18-fluorocyclobutane-carboxylic-acid; Axumin; Axumin-PET scan; FACBC; fluciclovine(18F); Fluciclovine-F-18; GE-148; Ge-148-18F; Ge-148-F-18; NMK-36; Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acidLatest Information Update: 01 Oct 2024
At a glance
- Originator Emory University
- Developer Blue Earth Diagnostics; Emory University; GE Healthcare; Memorial Sloan-Kettering Cancer Center; Nihon Medi-Physics; University of Arizona
- Class Amino acids; Carboxylic acids; Cyclobutanes; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
- Preregistration Glioma
- Phase III Brain metastases
- Phase II Bone metastases
- Phase I Breast cancer
- No development reported Glioblastoma; Head and neck cancer; Lung cancer; Parathyroid cancer
Most Recent Events
- 01 Oct 2024 Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics is still in phase I trials for Breast cancer (Diagnosis) in USA (IV, Injection)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in USA (IV, Injection)
- 21 Mar 2024 Emory University in collaboration with National Cancer Institute completes a phase-I trials in Breast cancer (Diagnosis) in USA (IV) (NCT04750473)